Authors' Reply – Comments: Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?

Saved in:
Bibliographic Details
Published inClinics (São Paulo, Brazil) Vol. 74; p. e1517
Main Authors Gomes, Luis Eduardo Miani, da Silva, Francesca Aparecida Ramos, Pascoal, Lívia Bitencourt, Ricci, Renato Lazarin, Nogueira, Guilherme, Camargo, Michel Gardere, de Lourdes Setsuko Ayrizono, Maria, Fagundes, João José, Leal, Raquel Franco
Format Journal Article
LanguageEnglish
Published Brazil Elsevier España, S.L.U 2019
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Faculdade de Medicina / USP
Elsevier España
Subjects
Antibodies, Monoclonal
Brazil
Comments
Crohn Disease
Humans
Immunosuppressive Agents
Infliximab
MEDICINE, GENERAL & INTERNAL
Brazil
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
ISSN:1807-5932
1980-5322
1980-5322
DOI:10.6061/clinics/2019/e1517